Why CLOV Stock dropped -2.62% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, CLOV scores 38 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 6 / 20 (ROIC -29.3%; FCF yield -2.84%). This is the weakest pillar and signals that the business is not currently converting capital into cash returns. For a prospective investor, this means the valuation rests on expectations of future improvement rather than present cash generation.
• Whale 13F Flow: 13 / 20 (Institutional accumulation & options positioning). This is a moderate score, indicating some institutional interest, though the source data does not itemize holdings (see Analyst View section).
• Insider Conviction: 3 / 20 (SEC Form 4 & Congressional PTR cluster flow). This is among the lowest scores and suggests limited insider-side conviction in the recent flow data.
• Macro Regime Fit: 8 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the broad market, so it offers no defensive cushion against market-wide drawdowns.
• Forensic Balance Sheet: 8 / 20 (Altman Z 3.62; Piotroski F 3/9; Debt/Equity 0.5). The Altman Z of 3.62 is above commonly cited distress thresholds, but the Piotroski F of 3/9 is weak, indicating limited fundamental strength across the checklist.

Taken together, the pillar profile suggests the principal upside drivers would be a sustained turn toward positive cash generation and improved margins, which the current data does not yet show. Valuation tradeoffs are significant: with negative ROIC and negative FCF yield, earnings-based multiples are not available in the source data, so valuation must be judged on other grounds. The 52-week range of $1.58 to $5.59 against a current price of 4.58 illustrates considerable price volatility. This is an analytical framing, not personalized advice.

Clover Health Investments Corp. (Class A) is classified in the Health Care sector and Medical Specialities industry, listed on NASDAQ under the ticker CLOV. Not available in source data for product detail, customer base, or revenue mechanics beyond sector classification. The revenue figures in the financial section indicate a substantial operating scale, but the source data does not specify the revenue model or payer structure.

Per the SEC financials, the company reported operating and net losses across the three periods shown, with FY 2024 showing positive free cash flow of $33.3M and FY 2025 reverting to negative free cash flow of $-69.0M. Reported net margin in the market data is -4.4%, and operating margin is -4.4%, while ROIC is -29.3%. Per the Roarable RQD rating, the Altman Z-Score is 3.62 and the Piotroski F-Score is 3/9, with Debt/Equity at 0.5. Cash declined from $194.5M in FY 2024 to $78.3M in FY 2025.

Per the recent news feed, the dominant theme is Medicare-related ratings news. Headlines reference a 5-star Medicare rating and a 5-star PPO CMS rating for 2027, with one report noting the stock rose 9.4% on the PPO rating. Other items cover the CEO selling $38,675 of CLOV shares and the unveiling of 2027 Medicare Advantage plans. Items are tagged as catalyst or market wire with light signals of YELLOW or GREEN. Risk watch items include the insider share sale and the stock's -4.38% change in the most recent session. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are recorded.

• What is the revenue model and payer mix behind the FY 2025 revenue of $1924.3M, and how much depends on Medicare Advantage reimbursement?
• What drove the swing in free cash flow from $33.3M in FY 2024 to $-69.0M in FY 2025?
• What are the EPS and debt figures, which are reported as N/A in the financial filings?
• How much of the recent 5-star rating news is already reflected in the current price after the -4.38% move?
• What is the consensus analyst view and who are the largest institutional holders?